Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2026 Apr 1;17:1769065. doi: 10.3389/fimmu.2026.1769065

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2026 Yang, Pan, Yang, Wang, Cheng and Qi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Six-panel scientific figure showing time-course line charts for various biomarkers and clinical measurements. Panel A: CK sharply decreases within 50 days, then stabilizes. Panel B: CKMB follows a similar rapid decline and plateau. Panel C: MYO drops steeply, then remains low. Panel D: AchR-Ab varies with an initial peak, gradual decline, and some fluctuation. Panel E: Four antibodies (JO-1, RO-52, nRNP, dsDNA) decrease over time, with dsDNA declining more gradually. Panel F: EF rises to near-normal range and maintains stability throughout the timeframe. All x-axes represent time in days. — Abnormal Indicator Changes and Core Variation Rules (Baseline to 9-Month Follow-Up) (A–C) CK, CKMB, MYO returned to normal within 40-50 days; (D) AchR-Ab decreased approximately 50%; (E) anti-JO-1, RO-52, dsRNA-Ab returned to normal; anti-nRNP-Ab decreased to twice the normal value; (F) LVEF returned to normal around day 70 and remained stable.